Skip to main content

Biggest successes in 2020 for biotechs in the Basel Area

| News

Biggest successes in 2020 for biotechs in the Basel Area

22.04.2021

Biotech companies in the Basel Area played a key role in the sector’s record performance in 2020. The latest Swiss Biotech Report has shown that they led the response to the coronavirus pandemic, received record levels of financing or were acquired by big pharma.

A review of the Swiss biotech sector for 2020 shows that the industry could hardly be in better shape. As the latest Swiss Biotech Report 2021 entitled “Agility, leadership and innovation in the time of Covid-19” reveals, the industry achieved top scores for nearly every category. In the Global Innovation Index, Switzerland claimed top spot in 2020 for the tenth year in a row. Biotech companies from the Basel Area had a major stake in this success.

The Report and accompanying press release issued by the Swiss Biotech Association underline the part Switzerland played in combating the coronavirus pandemic. In this context, the role of Bachem Holding AG from Bubendorf in the canton of Basel-Landschaft in responding to the pandemic through basic research and vaccine manufacture is highlighted. With regard to diagnostics, the work of Roche Pharma is noted.

Overall, investment in Swiss biotech companies almost tripled on the previous year’s figure. It amounted to 3.44 billion Swiss francs. Investment in research and development alone rose by 10 percent to 2.2 billion francs. Of the listed companies, Idorsia raised 866 million francs and Basilea Pharmaceutica raised 125 million francs. With 135 million francs, the biggest portion of the private capital was raised by Basel company VectivBio Holding AG, while  54 million francs went to another Basel-based company Noema Pharma, founded in July 2020.

Research carried out by the country’s biotech firms led to an 8 percent increase in jobs. At present, these companies employ 16,300 people. Moreover, they were involved in a series of mergers and acquisitions. The Japanese company Sumitomo Dainippon Pharma and Basel’s Roivant Sciences together formed the new company Sumitovant Biopharma. The deal was worth US$3 billion. In addition, Boehringer Ingelheim acquired Basel-based company NBE-Therapeutics for €1.2 billion.

The Swiss biotech industry generated revenues of 4.5 billion francs in 2020. Many companies suffered significant delays in their research and development pipeline, as Michael Altorfer, CEO of the Swiss Biotech Association explained. “Nonetheless, we are confident that the sector will continue its impressive expansion”.

The Swiss Biotech Report is jointly produced by ten Swiss companies and associations.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.